Viking Therapeutics (VKTX) Stock
Clinical-stage biotech targeting obesity and metabolic disorders. Here's the price, business snapshot, and what's worth knowing about Viking Therapeutics in October 2026.
Viking Therapeutics, Inc. (VKTX) is a clinical‑stage biopharmaceutical company focused on developing treatments for metabolic and endocrine disorders. With a market capitalisation of about $3.7 billion, Viking advances a pipeline of investigational candidates aimed at conditions such as metabolic liver disease, obesity and related cardiometabolic disorders. Investors should note the company’s profile is typical of small-cap biotech: progress and valuation depend heavily on clinical trial results, regulatory decisions and partnerships or licensing activity. Financial outcomes can be volatile as programmes move through clinical phases and require funding; Viking may raise capital or enter collaborations to support development. Key considerations include trial timelines, data readouts, the competitive landscape in metabolic disease, and management’s capital allocation. This summary is educational only and not personalised investment advice; biotech investments carry substantial risk and potential for significant price fluctuation.
Viking Therapeutics (VKTX) Stock Forecast
Analyst price target, next 12 months
$103.00
+322.1% vs today's $24.40
Price range over the last 12 months
Close to its 12-month low
Analysts covering Viking Therapeutics have a consensus 12-month target of $103.00, above the current price of $24.40.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Viking Therapeutics stock with a target price of $103, indicating strong potential for profit.
Financial Health
Viking Therapeutics is showing strong cash flow and book value, indicating solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts Ahead
Clinical trial readouts and regulatory milestones can materially move the stock, offering potential opportunities but also significant downside if results disappoint.
Growth & Volatility
Market capitalisation reflects expectations for future success; small‑cap biotech shares can swing widely, so consider risk tolerance and investment horizon.
Competitive Landscape
Metabolic and liver disease are active areas with competing approaches; regulatory and commercial dynamics will influence long‑term prospects.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
